The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2016 | iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies
Andrew Davies, MRCP, PhD of University Hospital of Southampton, Southampton, UK discusses his highlights from the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA. First, Dr Davies explains that the meeting is a great place for discussion. He highlights a session on novel immunotherapies and the discussion around CAR T-cell therapy and how to apply this technology. Further, he mentions bispecific antibodies (BiTEs) and novel monoclonal antibodies. He then highlights the talks on diffuse large B-cell lymphoma (DLBCL) and the application of the cell of origin as well as new technologies and their application in lymphoma, e.g. circulating tumor DNA.
